Report cover image

Global Age-Related Macular Degeneration (AMD) Therapeutics Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 193 Pages
SKU # APRC20561634

Description

Summary

According to APO Research, The global Age-Related Macular Degeneration (AMD) Therapeutics market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Age-Related Macular Degeneration (AMD) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Age-Related Macular Degeneration (AMD) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Age-Related Macular Degeneration (AMD) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Age-Related Macular Degeneration (AMD) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Age-Related Macular Degeneration (AMD) Therapeutics include Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd. and Bausch Health Companies, Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Age-Related Macular Degeneration (AMD) Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Age-Related Macular Degeneration (AMD) Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Age-Related Macular Degeneration (AMD) Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Age-Related Macular Degeneration (AMD) Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Age-Related Macular Degeneration (AMD) Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Age-Related Macular Degeneration (AMD) Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Age-Related Macular Degeneration (AMD) Therapeutics Segment by Company

Novartis AG
Amgen Inc.
Regeneron Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd.
Bausch Health Companies, Inc.
Age-Related Macular Degeneration (AMD) Therapeutics Segment by Type

Wet AMD
Dry AMD
Age-Related Macular Degeneration (AMD) Therapeutics Segment by Application

Clinic
Hospital
Research Institute
Other
Age-Related Macular Degeneration (AMD) Therapeutics Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Age-Related Macular Degeneration (AMD) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Age-Related Macular Degeneration (AMD) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Age-Related Macular Degeneration (AMD) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Age-Related Macular Degeneration (AMD) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Age-Related Macular Degeneration (AMD) Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Age-Related Macular Degeneration (AMD) Therapeutics revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Age-Related Macular Degeneration (AMD) Therapeutics Market by Type
1.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Wet AMD
1.2.3 Dry AMD
1.3 Age-Related Macular Degeneration (AMD) Therapeutics Market by Application
1.3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Research Institute
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Age-Related Macular Degeneration (AMD) Therapeutics Market Dynamics
2.1 Age-Related Macular Degeneration (AMD) Therapeutics Industry Trends
2.2 Age-Related Macular Degeneration (AMD) Therapeutics Industry Drivers
2.3 Age-Related Macular Degeneration (AMD) Therapeutics Industry Opportunities and Challenges
2.4 Age-Related Macular Degeneration (AMD) Therapeutics Industry Restraints
3 Global Growth Perspective
3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Perspective (2020-2031)
3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Growth Trends by Region
3.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2020-2025)
3.2.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Players
4.1.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Players (2020-2025)
4.1.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Players (2020-2025)
4.1.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Key Players Headquarters & Area Served
4.4 Global Age-Related Macular Degeneration (AMD) Therapeutics Players, Product Type & Application
4.5 Global Age-Related Macular Degeneration (AMD) Therapeutics Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market CR5 and HHI
4.6.3 2024 Age-Related Macular Degeneration (AMD) Therapeutics Tier 1, Tier 2, and Tier 3
5 Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
5.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2020-2031)
5.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2020-2031)
6 Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
6.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2020-2031)
6.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Novartis AG
7.1.1 Novartis AG Comapny Information
7.1.2 Novartis AG Business Overview
7.1.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (2020-2025)
7.1.4 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
7.1.5 Novartis AG Recent Developments
7.2 Amgen Inc.
7.2.1 Amgen Inc. Comapny Information
7.2.2 Amgen Inc. Business Overview
7.2.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (2020-2025)
7.2.4 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
7.2.5 Amgen Inc. Recent Developments
7.3 Regeneron Pharmaceuticals Inc.
7.3.1 Regeneron Pharmaceuticals Inc. Comapny Information
7.3.2 Regeneron Pharmaceuticals Inc. Business Overview
7.3.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (2020-2025)
7.3.4 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
7.3.5 Regeneron Pharmaceuticals Inc. Recent Developments
7.4 F. Hoffmann-La Roche Ltd.
7.4.1 F. Hoffmann-La Roche Ltd. Comapny Information
7.4.2 F. Hoffmann-La Roche Ltd. Business Overview
7.4.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (2020-2025)
7.4.4 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
7.4.5 F. Hoffmann-La Roche Ltd. Recent Developments
7.5 Bausch Health Companies, Inc.
7.5.1 Bausch Health Companies, Inc. Comapny Information
7.5.2 Bausch Health Companies, Inc. Business Overview
7.5.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (2020-2025)
7.5.4 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
7.5.5 Bausch Health Companies, Inc. Recent Developments
8 North America
8.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2020-2031)
8.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2020-2031)
8.2.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2020-2025)
8.2.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2026-2031)
8.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Type (2020-2031)
8.4 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2020-2031)
8.4.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2020-2025)
8.4.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2026-2031)
8.5 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Application (2020-2031)
8.6 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country
8.6.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2020-2025)
8.6.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2020-2031)
9.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2020-2031)
9.2.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2020-2025)
9.2.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2026-2031)
9.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Type (2020-2031)
9.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2020-2031)
9.4.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2020-2025)
9.4.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2026-2031)
9.5 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Application (2020-2031)
9.6 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country
9.6.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2020-2025)
9.6.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2020-2031)
10.2 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2020-2031)
10.2.1 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2020-2025)
10.2.2 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2026-2031)
10.3 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Type (2020-2031)
10.4 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2020-2031)
10.4.1 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2020-2025)
10.4.2 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2026-2031)
10.5 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2020-2031)
11.2 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2020-2031)
11.2.1 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2020-2025)
11.2.2 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2026-2031)
11.3 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Type (2020-2031)
11.4 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2020-2031)
11.4.1 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2020-2025)
11.4.2 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2026-2031)
11.5 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Application (2020-2031)
11.6 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country
11.6.1 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2020-2025)
11.6.3 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2020-2031)
12.2 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2020-2031)
12.2.1 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2020-2025)
12.2.2 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2026-2031)
12.3 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Type (2020-2031)
12.4 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2020-2031)
12.4.1 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2020-2025)
12.4.2 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2026-2031)
12.5 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Application (2020-2031)
12.6 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country
12.6.1 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2020-2025)
12.6.3 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.